TIDMPYC
RNS Number : 0019O
Physiomics PLC
27 May 2020
27 May 2020
Physiomics plc
("Physiomics") or ("the Company")
Fundraise
Physiomics completes GBP0.83m (gross) fundraise to fund growth
opportunities
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models and its Virtual Tumour(TM) technology to
support the development of cancer treatment regimens and
personalised medicine solutions, is pleased to announce that it has
completed a placing and subscription, conditional on Admission, to
raise approximately GBP828,750 (gross) from the issue of 23,678,571
new ordinary shares of 0.4p each ("Ordinary Shares") at an issue
price of 3.5p per share, through Hybridan LLP (the
"Fundraise").
In the last few years, the Company has made significant
progress, including:
-- 70% compounded annual growth in total income FY 2017- 2019,
culminating in its highest ever total income in FY 2019 of
GBP783k
-- >GBP1m of contracts announced with Merck KGaA since master
services agreement announced in November 2017
-- Significant new clients CellCentric Ltd (Apr 2018) and
Bicycle Therapeutics plc (June 2019) added and repeat contracts
signed with both
-- Completion of a second Innovate UK grant project focused on
personalised treatment of advanced prostate cancer (May 2019) and
subsequent presentation of results at NIHR event at Royal Marsden
Hospital
-- Award of NIHR i4i grant (March 2020) to undertake an
observational trial to generate data in support of personalised
dosing tool in advanced prostate cancer
-- Entering into discussions with companies with an established
presence in the field of personalised medicine with a view to
exploring how its technology could be commercialised
On 3 March 2020, the Company announced, as part of its unaudited
interim results statement, that it held cash and cash equivalents
of GBP434k as at 31 December 2019 and that it had achieved a small
positive cash inflow for the six months ended on the same date. On
19 March 2020, the Company further confirmed that it had a strong
pipeline of work and the Directors believe that this has been
further strengthened since that announcement.
In this regard, in the last two working days, the Company has
received a strong indication that a significant contract is likely
to be signed with a new large pharmaceutical client, with which it
has been in discussions since late 2019. While is it still possible
that the potential new client could withdraw, it is the Directors'
opinion that this is unlikely. Should the contract be signed, the
work is expected to take two of our technical staff around five
months to complete.
In order to further develop its business, the Company is raising
funds through the Fundraise to enable it to carry out activities
including increasing its sales & marketing spend, recruiting a
further member of its technical team and further investing in its
personalised medicine technology as well as for general working
capital purposes.
Director Participation in the Fundraise
Dr Jim Millen (CEO), Dr Paul Harper (Chairman) and Dr Christophe
Chassagnole (COO) have participated in the Fundraise in the amounts
of GBP3,000, GBP5,000 and GBP3,000 respectively (the "Directors'
Participation") and will be issued 85,715 Ordinary Shares, 142,857
Ordinary Shares and 85,715 Ordinary Shares respectively. On
Admission, Dr Millen, Dr Harper and Dr Chassagnole will be
interested in, in aggregate, 530,356, 668,564 and 602,723 Ordinary
Shares respectively, representing 0.55%, 0.70% and 0.63%, of the
Company's then enlarged issued share capital.
Admission and total voting rights
Application will be made for the new Ordinary Shares to be
admitted to trading on AIM and dealing is expected to commence on 3
June 2020 ("Admission"). Following Admission, the number of
Ordinary Shares in issue will increase to 95,588,965.
For the purposes of the Financial Services Authority's
Disclosure Guidance and Transparency Rules (the "DTRs"), the issued
ordinary share capital of the Company following Admission will
consist of 95,588,965 Ordinary Shares with voting rights attached
(one vote per Ordinary Share). There are no Ordinary Shares held in
treasury. This total voting rights figure may be used by
shareholders as the denominator for the calculations by which they
will determine whether they are required to notify their interests
in, or a change to their interest in, Physiomics under the DTRs.
The Company's share capital additionally comprises 2,481,657,918
deferred shares of 0.036p each which are not quoted and to which no
voting rights attach.
Dr Jim Millen, CEO said: "We are delighted by the response to
this over-subscribed fundraise. We thank our current shareholders
for their continued support and have achieved another milestone by
welcoming our first small-cap institutional fund onto the register.
We believe this is reflective of our strong commercial traction
over the last four years.
Our team is committed to continuing to support global pharma and
biotech companies in their drug discovery and development
endeavours, and these funds will be mainly focused on growing our
already strong pipeline of new business opportunities. I look
forward to continuing to update shareholders on our progress."
The information contained within this announcement is deemed to
constitute inside information as stipulated under the Market Abuse
Regulations (EU) No. 596/2014.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0)20 3764 2341
Notes to Editor
About Physiomics
Physiomics(R) is an oncology consultancy using mathematical
models and its Virtual Tumour(TM) technology to support the
development of cancer treatment regimens and personalised medicine
solutions. The predictive capability of Virtual Tumour has been
confirmed by 55 projects, involving over 25 targets and 60 drugs,
and has worked with clients such as Merck KGaA, Merck & Co,
Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 90 years collectively of working in
oncology and/or computational biology and over 100 publications in
peer reviewed journals.
For more information please visit:
www.physiomics-plc.com
www.twitter.com/Physiomics
www.linkedin.com/company/physiomics-plc/
PDMR/PCA FCA Transaction Notification
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Jim Millen
-------------------------------- -------------------------------------
2. Reason for the Notification
-----------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------------- -------------------------------------
b) Initial notification/amendment Initial notification
-------------------------------- -------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Physiomics plc
-------------------------------- -------------------------------------
b) LEI 213800A71DSZ6ABMTQ91
-------------------------------- -------------------------------------
4. Details of the transaction(s):section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv)each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the Financial Ordinary shares of 0.4p each in the
instrument, type of instrument share capital of the Physiomics plc
-------------------------------- -------------------------------------
Identification code ISIN: GB00BDR6W943
-------------------------------- -------------------------------------
b) Nature of the Transaction Issue of Ordinary shares
-------------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
3.5p 85,715
----------
-------------------------------- -------------------------------------
d) Aggregated information N/A - single issuance
Aggregated volume Price
-------------------------------- -------------------------------------
e) Date of the transaction 27 May 2020
-------------------------------- -------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
(XLON)
-------------------------------- -------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Paul Harper
-------------------------------- -------------------------------------
2. Reason for the Notification
-----------------------------------------------------------------------
a) Position/status Non-executive Chairman
-------------------------------- -------------------------------------
b) Initial notification/amendment Initial notification
-------------------------------- -------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Physiomics plc
-------------------------------- -------------------------------------
b) LEI 213800A71DSZ6ABMTQ91
-------------------------------- -------------------------------------
4. Details of the transaction(s):section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii)
each date; and (iv)each place where transactions have been
conducted
-----------------------------------------------------------------------
a) Description of the Financial Ordinary shares of 0.4p each in the
instrument, type of instrument share capital of the Physiomics plc
-------------------------------- -------------------------------------
Identification code ISIN: GB00BDR6W943
-------------------------------- -------------------------------------
b) Nature of the Transaction Issue of Ordinary shares
-------------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
3.5p 142,857
----------
-------------------------------- -------------------------------------
d) Aggregated information N/A - single issuance
Aggregated volume Price
-------------------------------- -------------------------------------
e) Date of the transaction 27 May 2020
-------------------------------- -------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
(XLON)
-------------------------------- -------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Christophe Chassagnole
-------------------------------- -------------------------------------
2. Reason for the Notification
-----------------------------------------------------------------------
a) Position/status Chief Operating Officer
-------------------------------- -------------------------------------
b) Initial notification/amendment Initial notification
-------------------------------- -------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name Physiomics plc
-------------------------------- -------------------------------------
b) LEI 213800A71DSZ6ABMTQ91
-------------------------------- -------------------------------------
4. Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv)each place where transactions have
been conducted
-----------------------------------------------------------------------
a) Description of the Financial Ordinary shares of 0.4p each in the
instrument, type of instrument share capital of the Physiomics plc
-------------------------------- -------------------------------------
Identification code ISIN: GB00BDR6W943
-------------------------------- -------------------------------------
b) Nature of the Transaction Issue of Ordinary shares
-------------------------------- -------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
3.5p 85,715
----------
-------------------------------- -------------------------------------
d) Aggregated information N/A - single issuance
Aggregated volume Price
-------------------------------- -------------------------------------
e) Date of the transaction 27 May 2020
-------------------------------- -------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
(XLON)
-------------------------------- -------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOESEIEEMESSESI
(END) Dow Jones Newswires
May 27, 2020 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024